Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine
- 28 November 2003
- journal article
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 11 (1) , 18-20
- https://doi.org/10.1038/sj.cdd.4401344
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Memantine in Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2003
- Excitotoxicity, apoptosis and neuropsychiatric disordersCurrent Opinion in Pharmacology, 2003
- Potential and Current Use of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Diseases of AgingDrugs & Aging, 2001
- The Role of Synaptic Proteins in Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2000
- Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism.The Journal of Physiology, 1997
- Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures.Proceedings of the National Academy of Sciences, 1995
- Excitatory Amino Acids as a Final Common Pathway for Neurologic DisordersNew England Journal of Medicine, 1994
- Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxideTrends in Neurosciences, 1993
- A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compoundsNature, 1993
- Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complexNeuron, 1992